- Home
- HSCS vs TCRT Comparison
HSCS vs TCRT Comparison
Compare HSCS & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | TCRT |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 6.7M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | HSCS | TCRT |
|---|---|---|
| Price | $2.25 | $2.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 7.2K | ★ 13.2K |
| Earning Date | 03-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | $1,072.41 | $5,680,500.00 |
| Revenue Next Year | $2,700.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.01 | $1.31 |
| 52 Week High | $6.47 | $5.48 |
Technical Indicators
Market Signals| Indicator | HSCS | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 27.17 | 44.25 |
| Support Level | $2.09 | $2.91 |
| Resistance Level | $3.28 | $3.15 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 3.57 | 18.17 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.